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Background. The efficacy of licensed direct-acting antiviral (DAA) regimens is assumed to be the same for hepatitis C virus 
(HCV)–monoinfected patients (HCV-Mono) and HIV/HCV-coinfected patients (HCV-Co). However, the high sustained viral re-
sponse (SVR) rates of DAA regimens and the small number of HIV-infected patients included in registration trials have made it 
difficult to identify predictors of treatment failure, including the presence of HIV.
Methods. We compared treatment outcomes for ledipasvir/sofosbuvir (LDV/SOF) against HCV G1 in treatment-naïve HCV-
Mono and HCV-Co without cirrhosis in a prospective registry of individuals receiving DAAs for HCV.
Results. Up to September 2017, a total of 17 269 patients were registered, and 1358 patients (1055 HCV-Mono/303 HCV-Co) 
met the inclusion criteria. Significant differences between HCV-Mono and HCV-Co were observed for age, gender, and G1 sub-
type distribution. Among HCV-Co, 99.0% were receiving antiretroviral therapy. SVR rates for LDV/SOF at 8 weeks did not differ 
significantly between HCV-Mono and HCV-Co (96.9% vs 94.0%; P = .199). However, the SVR rate for LDV/SOF at 12 weeks was 
significantly higher for HCV-Mono than HCV-Co (97.2% vs 91.8%; P = .001). A multivariable logistic regression model including 
age, sex, liver stiffness, G1 subtype, HCV-RNA, HIV, and treatment duration showed the factors associated with treatment failure to 
be male sex (adjusted odds ratio [aOR], 2.49; 95% confidence interval [CI], 1.27–4.91; P = .008) and HIV infection (aOR, 2.23; 95% 
CI, 1.13–4.38; P = .020).
Conclusions. The results of this large prospective study analyzing outcomes for LDV/SOF against HCV G1 in treatment-naïve 
noncirrhotic patients suggest that HIV infection is a predictor of treatment failure in patients with chronic hepatitis C.
Keywords. antiviral agents/administration & dosage/*therapeutic use; DAA; hepatitis C, chronic/*complications/*drug therapy; 
HIV infections/*complications; sustained virologic response.
The licensure of direct-acting antiviral agents (DAAs) marked a 
turning point in the treatment of infection by hepatitis C virus 
(HCV) [1]. This therapeutic innovation offered new prospects 
for the treatment of individuals coinfected by HCV and HIV, 
a difficult-to-treat population in the interferon plus ribavirin 
(RBV) era, with lower sustained viral response (SVR) rates 
and higher frequencies of serious adverse events than patients 
monoinfected with HCV [2–4].
Currently, it is recommended that coinfected persons re-
ceive the same treatment as monoinfected individuals, assuming 
that the efficacy of approved DAA regimens does not differ be-
tween the groups [5, 6]; although this is not entirely the case for 
American Association for the Study of Liver Diseases/Infectious 
Diseases Society of America guidelines in the United States, in 
which ledipasvir and sofosbuvir (LDV/SOF) for 8 weeks is not 
recommended for patients with HIV/HCV coinfection, regardless 
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of baseline HCV RNA level [6]. However, whether HIV infection 
is a predictor of treatment response to DAA regimens is difficult to 
assess owing to the high SVR rates associated with most licensed 
all-oral DAA-based regimens against HCV and the low number 
of clinical trials with DAA including both monoinfected and 
coinfected patients [7, 8]. As for real-world case series, some have 
found an association between HIV coinfection and lower SVR 
rates [9, 10], whereas in others, SVR rates were not significantly dif-
ferent between monoinfected and coinfected individuals [11–14].
We aimed to assess whether HIV infection is associated with 
failure of DAA therapy. Therefore, we focused on previously un-
treated noncirrhotic patients infected with HCV genotype 1, with 
or without HIV, who were treated with LDV/SOF. We adopted 
this approach because it provided a large enough sample size of 
patients and because we could easily control for some predictors 
of response, including genotype, type of regimen, presence of cir-
rhosis, previous exposure to anti-HCV therapy, and use of RBV.
METHODS
Design and Patient Selection
Patients were selected for this study from the Madrid Registry 
of Use of DAA for HCV (RUA-VHC), a compulsory prospec-
tive registry of individuals receiving DAAs for HCV infection in 
the region of Madrid created in November 2014 by the Madrid 
Regional Health Service (SERMAS). Providing baseline data for 
this online registry is mandatory for the retrieval of DAAs in 
hospital pharmacies. Likewise, providing exhaustive follow-up 
data is a condition for reimbursement. The decision to treat was 
made and the regimen selected by the treating physician ac-
cording to current guidelines.
Data collected prospectively in the RUA-VHC have been re-
ported in depth elsewhere [15]. In summary, baseline data in-
cluded demographics, whether the patient was HIV-infected 
and receiving antiretroviral therapy (ART), HCV genotype and 
subtype, HCV RNA load, history of anti-HCV therapy, liver fi-
brosis stage, and presence or absence of cirrhosis. The date of 
initiation and type of DAA regimen, use of RBV, and planned 
treatment duration were also recorded.
In September 2016, a case report form was used to collect 
the following HIV-related variables offline: HIV transmission 
category, Centers for Disease Control and Prevention (CDC) 
clinical category, baseline and nadir CD4+ T-cell counts, and 
baseline HIV viral load. In March 2017, the online registry 
was modified to include all the variables related to HIV infec-
tion mentioned above. Since then, this information has been 
registered prospectively. The study protocol was approved by 
the ethics committee of Hospital Universitario La Paz for the 
analysis of anonymous routine clinical data without written in-
formed consent for purposes of scientific publication.
In this analysis, patients included in the RUA-VHC were eli-
gible if they were age 18 years or older, were infected with HCV 
genotype 1, were noncirrhotic and previously untreated, were 
treated with LDV/SOF without ribavirin for 8 or 12 weeks, and 
were scheduled to finish treatment on or before September 31, 
2017.
Measurements
Fibrosis stage and cirrhosis were determined by liver biopsy or 
transient elastography (FibroScan, Echo-Sens, Paris, France). 
Cirrhosis was defined as liver stiffness >12.5 kPa or clinical ev-
idence of liver decompensation. The remaining liver stiffness 
cutoffs were as follows: ≤7 kPa, the cutoff to rule out null or 
mild fibrosis; <9.5 kPa, the cutoff to rule out advanced fibrosis–
cirrhosis [16].
HCV RNA was measured at baseline, at the end of therapy, 
and 12 weeks after completion of treatment. Real-time pol-
ymerase chain reaction assays for the quantification of HCV 
RNA included Roche COBAS AmpliPrep/COBAS TaqMan 
HCV (Roche Molecular Systems, Pleasanton, CA; lower 
limit of detection [LLOD], 15 IU/mL), Abbott RealTime 
HCV assay (Abbott Laboratories, Abbott Park, IL; LLOD, 
12 IU/mL), and Siemens Versant HCV RNA, version 1.0 
(Siemens Healthcare GmbH, Erlangen, Germany; LLOD, 15 
IU/mL).
Outcomes
Follow-up data in the online registry included the following: (i) 
SVR, defined as undetectable plasma HCV RNA at 12 weeks 
after completion of treatment; (ii) relapse, defined as detect-
able post-treatment HCV RNA after undetectable HCV RNA 
at the end of therapy; and (iii) viral breakthrough, defined as 
detectable HCV RNA at the end of therapy and at week 12. 
Discontinuations due to adverse events or for reasons other 
than adverse events, losses to follow-up, and deaths were also 
registered.
Statistical Analysis
When analyzing treatment effectiveness, any patient who 
initiated LDV/SOF therapy without confirmed SVR or 
missing outcome data was considered a treatment failure. 
Three multivariable logistic regression models were used to 
identify independent baseline factors associated with treat-
ment failure. The first model included variables that were as-
sociated with treatment failure in univariable analysis with 
P <  .05. The second model included variables that were as-
sociated with treatment failure in univariable analysis with 
P < .1. The third model was a fully adjusted model including 
age, sex, liver stiffness, HCV genotype, HCV RNA load, HIV 
infection, and treatment duration. Analyses were performed 
for the entire data set and for subgroups of treatment dura-
tion (8 and 12 weeks). Wald tests were used to derive P values. 
The analyses were performed using Stata, version 14 (Stata 
Corp, College Station, TX).
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RESULTS
Patient Characteristics
Up to September 2017, a total of 17  269 patients (13  720 
monoinfected patients and 3549 coinfected patients) initiated 
all-oral DAAs for treatment of HCV infection in 25 hospitals 
in the region of Madrid. Of these, 1358 patients (1055 
monoinfected patients and 303 coinfected patients) met the in-
clusion criteria (Supplementary Figure 1). A total of 272 of the 
1358 patients (20.0%) included in this study were also included 
in a paper describing the real-world outcomes of all-oral DAA-
based therapy in 2369 HIV/HCV-coinfected patients [15].
The baseline characteristics of the 1358 patients categorized 
by LDV/SOF treatment duration and by type of patient 
(monoinfected or coinfected) are shown in Table 1. Overall, 497 
patients were treated with LDV/SOF for 8 weeks (36.6%), and 
861 patients were treated with LDV/SOF for 12 weeks (63.4%). 
A  higher percentage of monoinfected patients (39.2%) than 
coinfected patients (27.4%) were treated with LDV/SOF for 
8 weeks.
In brief, 55.1% were men, and the median age was 56 years. 
The HCV subtype distribution was 1a (40.9%), 1b (55.7%), and 
1 not subtyped (3.5%). The median HCV RNA was 6.2 Log 
IU/mL, and 17.2% of patients had an HCV RNA >6 million 
IU/mL. A  total of 1320 (97.2%) patients underwent transient 
elastography at baseline. The median liver stiffness value was 
8.8 kPa, and 494 (37.4%) patients had a liver stiffness value ≥9.5 
kPa (but ≤12.5 kPa), which was indicative of advanced fibrosis. 
Statistically significant differences between monoinfected 
patients and coinfected patients were observed at baseline for 
age, gender, and genotype 1 subtype distribution (Table 1).
At baseline, 99.0% of coinfected patients were on ART. Full 
data on HIV-related characteristics were available for analysis 
from approximately half of the coinfected patients. No statisti-
cally significant differences were found between patients with 
complete HIV data and patients with incomplete HIV data for 
age, HCV genotype distribution, and HCV RNA load. However, 
patients with incomplete HIV data were more frequently male 
and had a lower liver stiffness value (Supplementary Table 1). 
Differences in mechanism of acquisition of HIV were found be-
tween coinfected patients treated for 8 or 12 weeks, with a lower 
proportion of injection drug use and a higher frequency of men 
who have sex with men among the former group (Table 2).
Treatment Response
LDV/SOF for 8 Weeks
Treatment responses to LDV/SOF for 8 weeks are shown in 
Figure 1A. A total of 497 patients (414 monoinfected patients 
and 83 coinfected patients) received SOF/LDV without RBV for 
8 weeks. Overall, the SVR rate of 8 weeks of therapy with SOF/
LDV was 96.4%, without significant differences in SVR rates 
found between monoinfected patients and coinfected patients 
(96.9% vs 94.0%; P = .199). There were no viral breakthroughs. 
The overall relapse rate was 2.8%, and no statistically significant 
differences in relapse rates were found between monoinfected 
patients and coinfected patients (2.2% vs 6.0%; P = .06). Only 
1 patient discontinued SOF/LDV owing to adverse events, and 
3 patients discontinued therapy for reasons not related to ad-
verse events. All 4 were monoinfected patients. Outcomes for 8 
weeks’ treatment with LDV/SOF without RBV for HCV geno-
type 1a and 1b analysis are shown in Figure 2A.
Table 1. Baseline Characteristics of 1358 Previously Untreated Noncirrhotic Patients Infected With HCV Genotype 1 and Treated With LDV/SOF
 
8 wk 12 wk Total
Total
Monoinfected 
Patients
Coinfected 
Patients Pa Total
Monoinfected 
Patients
Coinfected 
Patients Pa
Monoinfected and 
Coinfected Patients
Variables n = 497 n = 414 n = 83  n = 861 n = 641 n = 220  n = 1358
Age, median (IQR), y 56 (49–66) 59 (50–68) 50 (46–54) <.001 56 (50–68) 61 (52–71) 51 (48–54) <0.001 56 (50–67)
Male sex, No. (%) 258 (51.9) 192 (46.4) 66 (79.5) <.001 491 (57.0) 325 (50.7) 166 (75.4) <0.001 749 (55.1)
HCV genotype/subtype, No. (%)    <.001    <0.001  
 1a 160 (32.2) 95 (22.9) 65 (78.3)  395 (45.9) 224 (34.9) 171 (77.7)  555 (40.9)
 1b 322 (64.8) 311 (75.1) 11 (13.2)  434 (50.4) 398 (62.1) 36 (16.4)  756 (55.7)
 1 not subtyped 15 (3.0) 8 (1.9) 7 (8.4)  32 (3.7) 19 (3.0) 13 (5.9)  47 (3.5)
HCV RNA, No. (%)          
 Log IU/mL, median (IQR) 5.9 (5.4–6.4) 5.9 (5.4–6.3) 6.1 (5.6–6.5) .033 6.4 (6.0–6.8) 6.4 (5.9–6.8) 6.5 (6.0–6.8) 0.070 6.2 (5.7–6.6)
 >6 million IU/mL, No. (%) 18 (3.6) 12 (2.9) 6 (7.2) .054 216 (25.1) 154 (24.0) 62 (28.2) 0.220 234 (17.2)
Transient elastography, No. (%)          
 No 8 (1.6) 8 (1.9) 0  30 (3.5) 30 (4.7) 0  38 (2.8)
 Yes 489 (98.4) 406 (98.1) 83 (100.0)  831 (96.5) 611 (95.3) 220 (100.0)  1320 (97.2)
 Stiffness kPa, median (IQR) 8.6 (7.9–9.4) 8.6 (7.9–9.3) 8.6 (7.8–10.0) .582 9.1 (8.1–10.4) 9.1 (8.1–10.4) 9.0 (8.1–10.3) 0.534 8.8 (8.0–10.1)
 ≥9.5 kPa, No. (%) 121 (24.7) 94 (23.1) 27 (32.5) .071 373 (44.9) 284 (46.5) 89 (40.4) 0.123 494 (7.4)
Abbreviations: HCV, hepatitis C virus; IQR, interquartile range; LDV/SOF, ledipasvir/sofosbuvir.
aP values were derived from Pearson’s chi-square test or the nonparametric Mann-Whitney test for differences in categorical or continuous variables, respectively.
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Table 2. Baseline HIV-Related Characteristics of 303 Previously Untreated Noncirrhotic HIV/HCV-Coinfected Patients With HCV Genotype 1 Who Were 
Treated With LDV/SOF
Variable 8 wk 12 wk Total Pa
Variables n = 83 n = 220 n = 303  
HIV risk factor, No. (%)    .021
 Injection drug use 39 (47.0) 120 (54.5) 159 (52.5)  
 Men who have sex with men 8 (9.6) 4 (1.8) 12 (4.0)  
 Heterosexual relations 5 (6.0) 8 (3.6) 13 (4.3)  
 Transfusions 0 2 (0.9) 2 (0.7)  
 Unknown 31 (37.3) 86 (39.1) 117 (38.6)  
CDC clinical category, No. (%)    .305
 A 21 (25.3) 38 (17.3) 59 (19.5)  
 B 9 (10.8) 38 (17.3) 47 (15.5)  
 C 22 (26.5) 60 (27.3) 82 (27.1)  
 Unknown 31 (37.3) 84 (38.2) 115 (37.9)  
Nadir CD4+/mm3, No. (%)    .622
 >500 8 (9.6) 14 (6.4) 22 (7.3)  
 200–499 17 (20.5) 38 (17.3) 55 (18.1)  
 <200 27 (32.5) 84 (38.2) 111 (36.6)  
 Unknown 31 (37.3) 84 (38.2) 115 (38.0)  
Baseline CD4+/mm3, No. (%)     
 >500 22 (26.5) 75 (34.1) 97 (32.0) .057
 200–499 9 (10.8) 43 (19.5) 52 (17.2)  
 <200 2 (2.4) 7 (3.2) 9 (3.0)  
 Unknown 50 (60.2) 95 (43.2) 145 (47.9)  
 Known 33 (39.8) 125 (56.8) 158 (52.1) .008
 Median (IQR) 632 (474–847) 595 (372–819) 607 (389–822) .474
ART, No. (%)    .285
 No 0 3 (1.4) 3 (1.0)  
 Yes 83 (100.0) 217 (98.6) 300 (99.0)  
HIV-RNA, No. (%)     
 Unknown 31 (37.3) 81 (36.8) 112 (37.0) .932
 Known 52 (62.6) 139 (63.2) 191 (63.0)  
 Detectable 5 (9.6) 7 (5.0) 12 (6.3) .246
 Undetectable 47 (90.4) 132 (95.0) 179 (93.7)  
Abbreviations: ART, antiretroviral therapy; CDC, Centers for Disease Control and Prevention; HCV, hepatitis C virus.
aP values derived from Pearson’s chi-square test or the nonparametric Mann-Whitney test for differences in categorical or continuous variables, respectively.
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Figure 1. A, Outcomes for 8 weeks of treatment with sofosbuvir/ledipasvir without ribavirin for HCV genotype 1 in treatment-naïve, noncirrhotic patients. B, Outcomes 
for 12 weeks of treatment with sofosbuvir/ledipasvir without ribavirin for HCV genotype 1 in treatment-naïve, noncirrhotic patients. P values are derived from Pearson’s 
chi-square test. Abbreviations: AE, adverse event; CI, confidence interval; DC, treatment discontinuations (number [%]); HCV, hepatitis C virus; HCV-Co, HIV/HCV-coinfected 
patients; HCV-Mono, HCV-monoinfected patients; SVR, sustained viral response (number [%]).
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LDV/SOF for 12 Weeks
Treatment response to LDV/SOF for 12 weeks is shown in 
Figure 1B. A total of 861 patients (641 monoinfected patients 
and 220 coinfected patients) received SOF/LDV without RBV 
for 12 weeks. Overall, the SVR rate of 12 weeks of therapy with 
SOF/LDV was 95.8%. Statistically significant differences in SVR 
rates were found between monoinfected patients and coinfected 
patients (97.2% vs 91.8%; P = .001). Again, there were no viral 
breakthroughs. The overall relapse rate was 1.6%, and no sta-
tistically significant differences in relapse rates were found be-
tween monoinfected patients and coinfected patients (1.1% vs 
3.2%; P  =  .06). Five patients (0.6%) discontinued SOF/LDV 
owing to adverse events (2 monoinfected patients [0.3%] and 3 
coinfected patients [1.4%]; P = .11). Fifteen patients (1.7%) dis-
continued therapy for reasons not related to adverse events (9 
monoinfected patients [1.4%] and 6 coinfected patients [2.7%]; 
P  =  .23). Two coinfected patients died before SVR could be 
assessed: both died from complications of acute exacerbation of 
chronic obstructive pulmonary disease. Outcomes for 12 weeks 
of treatment with LDV/SOF without RBV for HCV genotype 1a 
and 1b are shown in Figure 2B.
Variables Associated With Treatment Failure
The results of the univariable and multivariable logistic regres-
sion models to identify baseline variables associated with treat-
ment failure for the full data set are shown in Table 3. In the 
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Figure 2. A, Treatment outcomes for 8 weeks of treatment with sofosbuvir/ledipasvir without ribavirin for HCV genotype 1a and 1b in treatment-naïve, noncirrhotic 
patients. B, Treatment outcomes for 12 weeks of treatment with sofosbuvir/ledipasvir without ribavirin for HCV genotype 1a and 1b in treatment-naïve, noncirrhotic patients. 
P values are derived from Pearson’s chi-square test. Abbreviations: AE, adverse event; CI, confidence interval; Coinfected patients, HIV/HCV-coinfected patients; DC, treat-
ment discontinuations (number [%]); HCV, hepatitis C virus; MoP, HCV-monoinfected patients.
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univariable analysis, male sex and the presence of HIV infection 
were the only variables significantly associated with increased 
odds of treatment failure. In all 3 multivariable models, male 
sex and HIV infection were the only variables significantly as-
sociated with increased odds of treatment failure. In the fully 
adjusted model, the adjusted odds ratio (aOR) of treatment 
failure for males in comparison with females was 2.49 (95% CI, 
1.27–4.91; P = .008). Likewise, the aOR of treatment failure for 
coinfected patients in comparison with monoinfected patients 
was 2.23 (95% CI, 1.13–4.38; P  =  .020). We also performed 
separate analyses to identify baseline variables associated with 
treatment failure according to treatment duration. Among 
patients treated for 8 weeks, male sex was the only variable in-
dependently associated with treatment failure (Supplementary 
Table 2). Among patients treated for 12 weeks, HIV infection 
was the only variable independently associated with treatment 
failure (Supplementary Table 3).
DISCUSSION
Whether HIV infection is associated with treatment failure 
of DAA therapy is a controversial issue. The C-WORTHY 
and C-EDGE CO-STAR studies, 2 of the few clinical trials 
with DAA that included both monoinfected and coinfected 
patients, revealed similar rates of sustained virological re-
sponse to grazoprevir and elbasvir in both groups [7, 8]. These 
results are not easy to interpret owing to issues of study design 
in the C-WORTHY study (different treatment durations, dif-
ferent doses of elbasvir, and the addition or not of ribavirin) 
[7] and the low number of coinfected patients included in the 
C-EDGE CO-STAR study [8]. Some real-world practice studies 
have found lower SVR rates with all-oral DAA-based therapy 
in coinfected patients than in monoinfected patients [9, 10], 
whereas in other studies, SVR rates were not significantly dif-
ferent between monoinfected and coinfected individuals [11–
14]. Again, the results of these studies are difficult to interpret 
owing to the lack of homogeneity in essential variables such as 
HCV genotype, liver disease severity, prior exposure to anti-
HCV therapy, and DAA regimen used.
We answered our research question by analyzing a large and 
homogeneous group of HCV genotype 1–infected treatment-
naïve noncirrhotic patients treated with LDV/SOF. We found 
lower SVR rates for LDV/SOF in coinfected patients than in 
Table 3. Results From Univariable and Multivariable Logistic Regression Models to Identify Independent Baseline Factors Predictive of Treatment Failure 
Considering the Whole Data Set (Monoinfected, Coinfected, 8 and 12 Weeks), 1358
Variable
Treatment Failures Univariable Multivariable Model 1a Multivariable Model 2b Multivariable Model 3c
No. (%) OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Age   .473      .441
 <45 4 (2.9) 1.00      1  
 45–54 23 (4.8) 1.69 (0.58–4.98)      1.64 (0.55–4.89)  
 ≥55 27 (3.6) 1.27 (0.44–3.67)      2.03 (0.67–6.15)  
Sex   .001  .008  .010  .008
 Female 12 (2.0) 1.00  1.00  1.00  1.00  
 Male 42 (5.6) 2.96 (1.54–5.67)  2.47 (1.27–4.82)  2.43 (1.24–4.77)  2.49 (1.27–4.91)  
Liver stiffness, kPaa   .300      .399
 <9.5 28 (3.4) 1.00      1  
 ≥9.5 25 (5.1) 1.52 (0.88–2.64)      1.48 (0.84–2.61)  
 Unknown 1 (2.6) 0.77 (0.10–5.82)      1.19 (0.15–9.27)  
HCV genotype   .079    .879  .722
 1b 22 (2.9) 1.00    1.00  1  
 1a 30 (5.4) 1.91 (1.09–3.34)    1.15 (0.60–2.19)  1.27 (0.65–2.49)  
 1 not subtyped 2 (4.3) 1.48 (0.34–6.50)    0.89 (0.19–4.07)  0.89 (0.19–4.10)  
HCV RNA IU/mL   .911      .676
 <6 000 000 45 (4.0) 1.00      1  
 ≥6 000 000 9 (3.8) 0.96 (0.46–1.99)      0.85 (0.40–1.82)  
HIV infection   <.001  .007  .024  .020
 No 31 (2.9) 1.00  1.00  1.00  1.00  
 Yes 23 (7.6) 2.71 (1.56–4.73)  2.20 (1.24–3.89)  2.08 (1.10–3.94)  2.23 (1.13–4.38)  
Treatment duration   .612      .850
 12 wk 36 (4.2) 1.00      1  
 8 wk 18 (3.6) 0.86 (0.48–1.53)      1.06 (0.57–1.96)  
Abbreviations: CI, confidence interval; HCV, hepatitis C virus; OR, odds ratio.
aMultivariable model 1 includes variables with a P value <.05 in the univariable analysis.
bMultivariable model 2 includes variables with a P value <.1 in the univariable analysis.
cMultivariable model 3 is a fully adjusted one, including every variable detailed in the first column.
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monoinfected patients, with most of the treatment failures in 
both groups being viral relapses. The independent association 
between HIV and treatment failure was found after adjustment 
for age, sex, liver stiffness, HCV subtype, HCV RNA load, and 
treatment duration.
Interestingly, when we carried out separate analyses ac-
cording to treatment duration, we found an association be-
tween HIV and treatment failure among patients treated for 
12 weeks but not among patients treated for 8 weeks. This 
could be due to a type 2 error, as the number of HIV-infected 
patients treated for 8 weeks was substantially lower than the 
number treated for 12 weeks (83 vs 220). However, it must 
be considered that in comparison with patients treated for 8 
weeks, those treated for 12 weeks, irrespective of whether they 
were HIV-infected, had a significantly higher frequency of 
both HCV-RNA >6 million IU/mL and a liver stiffness value 
>9.5 kPa, which is indicative of advanced fibrosis. Moreover, 
among HIV-infected individuals, the proportion of MSM was 
higher in those treated for 8 weeks than in those treated for 
12 weeks. Given the recent ongoing outbreak of HCV among 
HIV-infected MSM, it is conceivable that more recent HCV 
infections were included in the former group than in the latter. 
This, in turn, could have influenced SVR rates, as treatment of 
acute or early HCV infection has been associated with very 
high SVR rates [17]. For these reasons, any potentially disad-
vantageous influence of HIV infection on treatment response 
would be more easily detected in patients treated for 12 weeks 
than in patients treated for 8 weeks.
The reason why HIV infection influenced treatment re-
sponse could not be ascertained from our data. However, this 
observation could be explained by some characteristics of 
coinfected patients, such as a CD4+ count <200 cells/mm3 and 
prior clinical AIDS, which are indicative of immunosuppres-
sion and have been associated with failure of all-oral DAA-
based therapy in coinfected patients [15]. Of note, 82 of the 
188 (43.6%) coinfected patients for which the CDC clinical 
category was known had a prior diagnosis of AIDS. Likewise, 
9 of the 158 (5.7%) coinfected patients with known CD4+ cell 
counts at baseline had <200 CD4+ cells/mm3. There is some 
evidence that the host immune response may play a role in 
HCV clearance even during DAA-based therapies, possibly 
through the recognition and elimination by T cells of viral 
variants with resistance-associated substitutions (RAS) [18]. 
Of note, in a recent analysis of clinical trials of patients with 
genotype 1 HCV infection treated with LDV/SOF, NS5A RAS 
were present in 8%–16% of patients before treatment and had 
a negative impact on treatment outcome [19]. If less effective 
clearance of resistant viral variants by the immune system is 
the reason why HIV infection negatively affected treatment 
response, then the newer pan-genotypic drug regimens that 
include NS5A inhibitors with a high barrier to resistance 
(eg, sofosbuvir/velpatasvir or glecaprevir/pibrentasvir) could 
be a preferred option over other recommended regimens in 
coinfected patients with a prior diagnosis of AIDS and/or a 
CD4+ cell count <200 CD4+ cells/mm3.
Our study is limited by the lack of data on adherence and on 
concomitant medication, including proton pump inhibitors 
[20]. Another limitation is the absence of information on 
preexisting viral variants with RAS, which prevented us 
from analyzing their prevalence among groups and assessing 
their impact on treatment outcomes. Our study is also lim-
ited by the fact that full data on HIV-related characteristics 
at the time of the data analysis were available for only half of 
the patients. This precluded the performance of additional 
comparative analyses between monoinfected patients and 
coinfected patients with a baseline CD4+ cell count below 
and above 200 cells/mm3, or with and without a prior diag-
nosis of clinical AIDS, for better assessment of the effect of 
immunosuppression on treatment response among coinfected 
individuals. Finally, another limitation is the absence of in-
formation about the mechanism of transmission of HCV in 
HCV-monoinfected persons.
Nevertheless, to our knowledge, ours is the largest real-world 
study comparing treatment outcomes between monoinfected 
and coinfected patients in which there was no variability ac-
cording to HCV genotype, liver disease severity, exposure to 
previous anti-HCV therapy, or DAA-based regimen.
In conclusion, the results of this study analyzing treatment 
outcomes for LDV/SOF against HCV genotype 1 in treatment-
naïve noncirrhotic patients suggest that HIV infection is a pre-
dictor of treatment failure in patients with chronic hepatitis 
C. This finding cannot be used to support the notion that HIV/
HCV-coinfected individuals are a difficult-to-treat popula-
tion in the era of all-oral DAA-based therapy. However, it does 
argue in favor of prioritizing the use of newer simplified and 
pan-genotypic anti-HCV regimens among coinfected patients 
to lessen the possibility of treatment failure due to suboptimal 
adherence or presence of resistant viral variants.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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APPENDIX. PHYSICIANS AND HOSPITAL 
PHARMACISTS OF THE MADRID REGISTRY OF USE 
OF DAA FOR HCV (RUA-VHC)
Hospital General Universitario Gregorio Marañón: 
Ahumada, Adriana; Ais Larisgoitia, Arantza; Aldámiz 
Echevarría Lois, María Teresa; Bañares Cañizares, Rafael; 
Berenguer Berenguer, Juan; Blanco Sánchez, Germán; 
Chamorro De Vega, Esther; Clemente Ricote, Gerardo; Collado 
Borell, Roberto; Díaz Fontenla, Fernando; Escudero Vilaplana, 
Vicente; Eworo Ndongo, Alia; Fernández Cruz, Ana; Flores 
Fernandez, Virginia; García González, Xandra; García Sánchez, 
Raquel; Gijón Vidaurreta, Paloma; Giménez Manzorro, Álvaro; 
Herranz Alonso, Ana; Ibáñez García, Sara; Lallana Sainz, Elena; 
Lobato Matilla, María Elena; López Bernaldo De Quirós, Juan 
Carlos; Manrique Rodríguez, Silvia; Martínez Fernandez-
Llamazares, Cecilia; Martínez Ortega, Pilar; Miralles Martin, 
Pilar; Montilla De Mora, Pedro; Padilla Ortega, Belén; Parras 
Vázquez, Francisco; Pérez Valderas, María Dolores; Revuelta 
Herrero, José Luis; Ribed Sánchez, Almudena; Rincón 
Rodríguez, Diego; Rodríguez González, Carmen; Romero 
Cristóbal, Mario; Romero Jiménez, Rosa; Ruiz Martínez, 
Cristina; Salcedo Plaza, Magdalena; Sánchez Somolinos, Mar; 
Sarobe González, Camino; Valerio Minero, Maricela. Hospital 
Universitario La Paz: Baladé Martinez, Laura; Barreiro García, 
Pablo; Benítez García, Beatriz; Bernardino De La Serna, José; 
Castillo Grau, Pilar; De Sebastián Rueda, María; Erdozain Sosa, 
José Carlos; Freire González, Mercedes; Gabaldón Garnica, 
Paloma; García Sánchez, Araceli; García-Samaniego Rey, 
Francisco; González Del Valle, Luis; González Fernández, María 
Ángeles; González García, Juan J.; Jiménez Nacher, Inmaculada; 
Jiménez Vicente, Carlos; Lucena Martinez; Patricia; Martín 
Carbonero, Luz; Molina Cabezuelo, Marta; Montes Ramírez, 
Mª Luisa; Moreno Celda, Victoria; Moreno Palomino, Marta; 
Moreno Ramos, Francisco; Olveira Martín, Antonio; Parrilla, 
Mercedes; Pérez Valero, Ignacio; Rodríguez Martín, Elena; 
Rodríguez Nava, José Luis; Romero Portales, Miriam; Rossignoli 
Montero, Ana; Ruiz De Hoyos, Marta; Sobrino Jiménez, 
Carmen; Soriano Vázquez, Vicente; Valencia Ortega, Eulalia; 
Varela Fernandez, Hugo Adolfo. Hospital Ramón y Cajal: 
Albillos Martinez, Agustín; Anguita Ruiz, Eva; Arocena 
Aranguren, Carlos; Casado Osorio, José; Díaz De Santiago, 
Alberto; Fortún Abete, Jesús; García González, Miguel; Gea 
Rodríguez, Francisco; Gómez De Salazar López De Silanes, 
María Esther; Gramage Caro, Teresa; Graus Morales, Javier; 
Moreno Guillen, Santiago; Moreno Zamora, Ana María; Navas 
Elorza, Enrique; Pérez Elías, María Jesús; Pérez Molina, José 
Antonio; Quereda Rodríguez-Navarro, Carmen; Rodríguez 
Sagrado, Miguel Ángel; Serrano Villar, Sergio Daniel; Vélez 
Díaz-Palleres, Manuel; Vivancos Gallego, María Jesús. Hospital 
doce de octubre: Campo Angora, Mercedes; Castellano 
Tortajada, Gregorio; De Lagarde Sebastián, María; Fernández 
Vázquez, Inmaculada; Gómez Valbuena, Isabel; Manzano 
Alonso, María Luisa; Martin Algíbez, Ana María; Matarranz 
Del Amo, Mariano; Muñoz Gómez, Raquel; Pinar López, Oscar; 
Pulido Ortega, Federico; Rubio García, Rafael; Serrano Garrote, 
Olga. Hospital Clínico de San Carlos: Benítez Giménez, María 
Teresa; Cabello Clotet, Noemí; Cuenca Alarcón, Francisca; 
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Devesa Medina, María José; Estrada Pérez, Vicente; Izquierdo 
Rubio, Sonia; Maroto Castellanos, Maite; Núñez Orantos, María 
José; Rodríguez Del Rio, Elena; Sáenz De Tejada López, Marta; 
Sánchez-Pobre Bejarano, Pilar; Santiago Pérez, Alejandro; 
Téllez Molina, María Jesús; Vergas García, Jorge. Hospital 
fundación Jiménez díaz: Álvarez Álvarez, Beatriz; Arias 
Moya, María Ángeles; Becares Martínez, Francisco Javier; 
Bonilla Porras, Macarena; Cabello Úbeda, Alfonso; Calvo 
Hernández, Rocío; González Guirado, Agustina; Górgolas 
Hernández, Miguel De; Hernández Segurado, Marta; Moran 
Ortiz-Desolorzano, Marta; Morón Merchante, Francisco Javier; 
Polo Lorduy, Benjamín Arturo; Porres Cubero, Juan Carlos; 
Tortajada Esteban, Elena Victoria; Varela Silva, Andrés 
L.  Hospital infanta Leonor: Barrio Antoranz, José; Barrueco 
Fernandez, Nélida; Cañamares Orbis, Irene; Carrión Alonso, 
Gemma; Cuevas Tascón, Guillermo; Escobar Rodríguez, Ismael; 
Esteban Alba, Concepción; Izquierdo García, Elsa; Liras 
Medina, Ángel; Lozano Maya, María Del Mar; Marino Martínez, 
Carolina; Ryan Murúa, Pablo; Sáez De La Fuente, Javier; 
Sánchez Rubio, Luis; Such Díaz, Ana; Tejedor Prado, Pilar; 
Troya García, Jesús; Villa Poza, José Carlos. Hospital de Puerta 
de Hierro: Arias Milla, Ana; Baños Pérez, Isolina; Benítez 
Gutiérrez, Laura María; Calleja Panero, José Luis; Cuervas 
Mons Martínez, Valentín; Duca, Ana María; Folguera Olías, 
Carlos; Menchén Viso, Belén; De La Revilla Negro, Juan; Ruiz 
Gutiérrez, Julia; Sánchez Guerrero, Amelia; Santiago Prieto, 
María Elvira. Hospital La Princesa: Alañón Plaza, Estefanía; 
Gallego Aranda, Tomás; García Buey, Luisa Consuelo; González 
Moreno, Leticia; Ibáñez Zurriaga, Amparo; Marinero Martinez-
Lázaro, Almudena; Martinez Nieto, Concepción; Morell 
Baladrón, Alberto; Pérez Abanades, María; Ramírez Herráiz, 
Esther; Real Martinez, Yolanda; Santos Gil, Ignacio De Los. 
Hospital U. Príncipe de Asturias: Arranz Caso, José Alberto; 
Beceiro Pedreño, Inmaculada; Borrego Rodríguez, Gloria; 
Casas García, Esperanza; Costero Pastor, Ana Belén; De Miguel 
Prieto, Julio; Del Pozo Prieto, David; Fernández Pacheco 
Garcia-Valdecasas, María; Ginés Palomares, Ana; Hernández 
Gutiérrez, Cristina; Herranz Muñoz, Clara; Herrero Fernández, 
Marta; Lebrero García, Alberto; Novella Mena, María; Ortiz 
Campos, María; Pérez Pérez, Diana; Poves Martinez, Elvira; 
Santolaya Perrín, María Rosario; Sanz Moreno, José; Víctor 
Palomares, Virginia. Hospital fundación de Alcorcón: Alonso 
López, Sonia; Bartolomé García, Emma; Fernández Rodríguez, 
Conrado; Gutiérrez García, Mª Luisa; Henríquez Camacho, 
Cesar Augusto; Hervás Gómez, Rafael; Losa García, Juan 
Emilio; Moreno Núñez, Leonor; Pérez Encinas, Montserrat; 
Polanco Paz, María Del Mar; Sanmartín Fenollera, Patricia; 
Velasco Arribas, María. Hospital infanta Sofía: Albertos 
Rubio, Sonia; Beltrán Castaño, Rocío; Comas Redondo, 
Carmen; García Yubero, Cristina; González-Ruano Pérez, 
Patricia; Hidalgo Aguirre, Lorena; Malmierca Corral, Eduardo; 
Martinez Hernández, Alicia; Pérez Álvarez, Mónica; Portillo 
Horcajada, Laura; Suárez García, Inés María. Hospital de 
fuenlabrada: Andrés Rosado, Ana; Canalejo Castrillero, 
Eduardo; Candel García, Beatriz; Carrasco Torrents, América; 
De La Poza Gómez, Gema; García Rebolledo, Eva María; 
Hernández Muniesa, Belén; Hinojosa Mena-Bernal, Juan; 
Mondejar Gutiérrez, Gemma María; Ontanon Nasarre, Ana; 
Piqueras Alcohol, Belén; Ruiz Giardin, José Manuel; Ruiz, Justo; 
San Martin López, Juan Víctor; Valer López-Fando, María Paz. 
Hospital Universitario de Getafe: Diez Fernandez, Raúl; 
Esteban Fernandez, Francisco Javier; Gaspar Alonso-Vega, 
Gabriel; Gil Ares, Fernando; Gómez Rubio, Mariano; Molina 
García, Teresa; Negro Vega, Eva; Pérez Caballero, Gloria; 
Sánchez Ayuso, Javier; Sánchez-Rubio Ferrández, Javier. 
Hospital Severo ochoa: Agud Aparicio, José Luis; Aguirre 
Losada, Alberto Ángel; Castro Urda, José Luis; Cervero Jiménez, 
Miguel; Díaz Gómez, Estrella; Domínguez Gozalo, Andrea; 
García Benayas, Elena; Jusdado Ruiz-Capillas, Juan José; Muñoz 
Romero, Javier; Torres Perea, Rafael. Hospital de Móstoles: 
Barros Aguado, Carlos Antonio; Corrales Pérez, Laura; Crespo 
Robledo, Paloma; González Alonso, Raquel; Mañes Sevilla, 
Mireya; Merino Morales, Francisco; Moreno Sánchez, Diego; 
Moriel Sánchez, Carmen; Rubio Cebrián, Beatriz. Hospital del 
Henares: Campos Fernández De Sevilla, María De Los Ángeles; 
De Lorenzo Pinto, Ana; Delgado Téllez De Cepeda, Laura; 
Egües Lugea, Amaia; Gallego Úbeda, Marta; Ibáñez Pinto, 
Alberto; Sánchez Gómez, Argeme; Sanz Rojas, Patricia; Serrano 
Herranz, Regino; Tovar Pozo, María; Valbuena González, 
Marta. Hospital infanta Cristina: Botella Mateu, Belén; 
Cuenca Morón, Beatriz De; De Guzmán García-Monge, María 
Teresa; Domingo Senra, Daniel; Domínguez García, Nuria; 
Esteban Fernandez-Zarza, Carlos; Martínez Consuegra, José 
Antonio; Matilla García, Elena; Melero Bermejo, José Antonio; 
Moreno Díaz, Raquel; Ortiz Duran, María; Pérez Quero, José 
Luis; Rodríguez Vargas, Blanca. Hospital del Sureste: Buendía 
Bravo, Silvia; Calvo Ramos, Irina; Capilla Montes, Cristina; 
Cruz Cruz, María Teresa; Díaz Sánchez, Antonio; Fernández 
Amago, María Teresa; García Benayas, María Teresa; González 
Alonso, María Rosario; Marzal Alfaro, Belén; Moya Valverde, 
Eloísa; Peñalver Cifuentes, Rafael; Rivero Fernández, Miguel. 
Hospital Rey Juan Carlos: García Barquero, Margarita; García 
García, Almudena; Gotuzzo Altez, Luis Ricardo; Huertas 
Velasco, María Antonia; Marcos Rojas Rodríguez De Quesada, 
Jorge; Nistal Juncos, Sara; Pérez Rial, Gabriel. Hospital infanta 
Elena: Alarcón Del Amo, Cristina; Alcalde Rodríguez, Daniel; 
Barranco Cao, Raquel; Calvache Rodríguez, Almudena; Chico 
Álvarez, Inmaculada; Collados Arroyo, Virginia; Del Portillo 
Rubí, Álvaro; Delgado Galán, María; López Martin, María Del 
Carmen; Rodríguez Rodríguez, Raquel; Tejedor Bravo, Marta; 
Vegas Serrano, Ana. Hospital de Torrejón: Achécar Justo, 
Linette María; Arponen, Sari; Blasco Guerrero, Marta; Del Rio 
Izquierdo, María; Esteva Jiménez, Laura; Gimeno García, 
Alejandra; González Pino, Andrea; Montero Hernández, María 
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Carmen; Morales Martínez, Lorena; Sáez Bertrand, Catalina. 
Hospital del Tajo: Alonso Grandes, Elena; Fernández Esteban, 
Eva; Lo Iacono, Oreste; Monsalvo Arroyo, Raquel; Pedraza 
Cezón, Luis Antonio; Soto Fernández, Susana; Terrancle Juan, 
Ignacio. Hospital Gómez Ulla: García Mayor, María De Los 
Ángeles; López Honduvilla, Francisco José; Menéndez 
Martínez, María Antonia; Pérez Moran, María José; Prats 
Olivan, Pilar. Hospital Collado Villalba: Abad Guerra, Javier; 
Arias Rivera, María Luisa; Bejerano Domínguez, Alicia; Correa 
Abanto, Lizbeth Milagros; Ferrere González, Federico; Gómez 
Pérez, Marta; Olivares Valles, Ana. Hospital El Escorial: 
Aguilar Guisado, Carolina; Belda Bilbao, Luis Miguel; Calvo 
Fernández, Santiago; García De Aguinaga, Mª Luisa; García 
Gimeno, María Mercedes; Gongorra López, Andrea; Jaime 
Sánchez, Belén; Montero Jiménez, Francisco Javier; Sánchez 
Suárez, Susana. Hospital Central de La Cruz Roja: Fuentes 
Irigoyen, Raquel; Iborra Herrera, Jerónimo; Navarrete García, 
Elena; Tejada González, Pilar. Hospital infantil Niño Jesús: 
García Rodríguez, María Del Pilar; Muñoz Codoceo, 
Rosa Ana.
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